-
Something wrong with this record ?
Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site
L. Phondeth, R. Kamaraj, J. Nilles, J. Weiss, WE. Haefeli, P. Pávek, D. Theile
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 2002-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2002-01-01 to 1 year ago
- MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism MeSH
- Rhodamine 123 metabolism MeSH
- Rifabutin * pharmacology MeSH
- Rifampin * pharmacology MeSH
- Molecular Docking Simulation MeSH
- Publication type
- Journal Article MeSH
Physiology-based pharmacokinetic modeling suggests that rifabutin can out-balance P-glycoprotein (P-gp) induction by concurrent P-gp inhibition. However, clinical or experimental evidence for this Janus-faced rifabutin effect is missing. Consequently, LS180 cells were exposed to a moderately (2 μM) and strongly (10 μM) P-gp-inducing concentration of rifampicin or rifabutin for 6 days. Cellular accumulation of the fluorescent P-gp substrate rhodamine 123 was evaluated using flow cytometry, either without (induction only) or with adding rifamycin drug to the cells during the rhodamine 123 efflux phase (induction + potential inhibition). Rhodamine 123 accumulation was decreased similarly by both drugs after 6-day exposure (2 μM: 55% residual fluorescence compared to non-induced cells, P < 0.01; 10 μM: 30% residual fluorescence compared to non-induced cells, P < 0.001), indicating P-gp induction. Rhodamine 123 influx transporters mRNA expressions were not affected, excluding off-target effects. Acute re-exposure to rifabutin, however, considerably re-increased rhodamine 123 accumulation (2 μM induction: re-increase by 55%, P < 0.01; 10 μM induction: 49% re-increase, P < 0.001), suggesting P-gp inhibition. In contrast, rifampicin only had weak effects (2 μM induction: no re-increase; 10 μM induction: 16% re-increase; P < 0.05). Molecular docking analysis eventually revealed that rifabutin has a higher binding affinity to the inhibitor binding site of P-gp than rifampicin (ΔG (kcal/mol) = -11.5 vs -5.3). Together, this study demonstrates that rifabutin can at least partly mask P-gp induction by P-gp inhibition, mediated by high affinity binding to the inhibitory site of P-gp.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007822
- 003
- CZ-PrNML
- 005
- 20240423160311.0
- 007
- ta
- 008
- 240412s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00204-023-03618-w $2 doi
- 035 __
- $a (PubMed)37833491
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Phondeth, Lottida $u Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- 245 10
- $a Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site / $c L. Phondeth, R. Kamaraj, J. Nilles, J. Weiss, WE. Haefeli, P. Pávek, D. Theile
- 520 9_
- $a Physiology-based pharmacokinetic modeling suggests that rifabutin can out-balance P-glycoprotein (P-gp) induction by concurrent P-gp inhibition. However, clinical or experimental evidence for this Janus-faced rifabutin effect is missing. Consequently, LS180 cells were exposed to a moderately (2 μM) and strongly (10 μM) P-gp-inducing concentration of rifampicin or rifabutin for 6 days. Cellular accumulation of the fluorescent P-gp substrate rhodamine 123 was evaluated using flow cytometry, either without (induction only) or with adding rifamycin drug to the cells during the rhodamine 123 efflux phase (induction + potential inhibition). Rhodamine 123 accumulation was decreased similarly by both drugs after 6-day exposure (2 μM: 55% residual fluorescence compared to non-induced cells, P < 0.01; 10 μM: 30% residual fluorescence compared to non-induced cells, P < 0.001), indicating P-gp induction. Rhodamine 123 influx transporters mRNA expressions were not affected, excluding off-target effects. Acute re-exposure to rifabutin, however, considerably re-increased rhodamine 123 accumulation (2 μM induction: re-increase by 55%, P < 0.01; 10 μM induction: 49% re-increase, P < 0.001), suggesting P-gp inhibition. In contrast, rifampicin only had weak effects (2 μM induction: no re-increase; 10 μM induction: 16% re-increase; P < 0.05). Molecular docking analysis eventually revealed that rifabutin has a higher binding affinity to the inhibitor binding site of P-gp than rifampicin (ΔG (kcal/mol) = -11.5 vs -5.3). Together, this study demonstrates that rifabutin can at least partly mask P-gp induction by P-gp inhibition, mediated by high affinity binding to the inhibitory site of P-gp.
- 650 12
- $a rifampin $x farmakologie $7 D012293
- 650 12
- $a rifabutin $x farmakologie $7 D017828
- 650 _2
- $a rhodamin 123 $x metabolismus $7 D020112
- 650 _2
- $a P-glykoprotein $x metabolismus $7 D020168
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kamaraj, Rajamanikkam $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 50005, Hradec Kralove, Czech Republic
- 700 1_
- $a Nilles, Julie $u Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany $u Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
- 700 1_
- $a Weiss, Johanna $u Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- 700 1_
- $a Haefeli, Walter E $u Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- 700 1_
- $a Pávek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 50005, Hradec Kralove, Czech Republic
- 700 1_
- $a Theile, Dirk $u Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. dirk.theile@med.uni-heidelberg.de $1 https://orcid.org/0000000347209242
- 773 0_
- $w MED00009265 $t Archives of toxicology $x 1432-0738 $g Roč. 98, č. 1 (2024), s. 223-231
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37833491 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160307 $b ABA008
- 999 __
- $a ok $b bmc $g 2081677 $s 1217589
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 98 $c 1 $d 223-231 $e 20231014 $i 1432-0738 $m Archives of toxicology $n Arch Toxicol $x MED00009265
- LZP __
- $a Pubmed-20240412